維京 (VKTX) Q3 2026 財報電話會議逐字稿
在 Q3 2026 財報電話會議中，維京治療討論其減肥藥物 VK2735 顯示最高可減重 22%，且給藥頻率較低。
fool.com ·
支援資產
開啟 Mo
Viking Therapeutics
24/7
-
-所選期間
-相較美股收盤
新聞
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial Progress
Viking Therapeutics reported a third quarter 2026 net loss of $183.2 million and confirmed that enrollment is complete in its VK2735 injectable clinical trials.
tradingview.com ·
代幣
- 代幣
- VKTXc
- 每枚代幣對應股數
- 1.00000000 VKTX